¶íÂÞ˹¹ó±ö»á¼¯ÍÅ

1-1311251432123M-lp
1-1311251432123M-lp
English ¶íÂÞ˹¹ó±ö»á¼¯Íż¯ÍÅÆóÒµÓÊÏä
icon_searchclose

ÔÙÉúÒ½ÁƼ¼Êõ¹²Í¬Î¢Á£Æ¤ÅàÖ²½¨¸´Æ¤·ôÂýÐÔÀ£Ññ´´ÃæµÄÁÙ´²·ÖÎö

2013Äê-11ÔÂ-25ÈÕ ÆðÔ´£º¶íÂÞ˹¹ó±ö»á¼¯ÍŹú¼Ê¼¯ÍÅ

ÄÏ·½Ò½¿Æ´óѧÖÐҽҩѧԺ£¬ºÎÈÊÁÁ  Ñî¡¡Áø;  ÓÜÁÖÊÐ»ÆÆÔÈËÃñÒ½Ôº£¬ÓàÖ¾ºÍ£¬ÁõÓ¢Ï飬Àî·ï´º
  ÕÑͨÖÐÒ½Ò©´óѧ´ÓÊôµÚ¶þÒ½Ôº£¬ÀîºìÒã

¡¾ÌáÒª¡¿¡¡Ö÷ÕÅ£ºÌ½ÇóÔÙÉúÒ½ÁƼ¼Êõ¹²Í¬×ÔÌå΢Á£Æ¤ÅàÖ²±íƤ»¯ÔÚÆ¤·ôÂýÐÔÀ£Ññ´´Ã潨¸´Ò½ÖÎÖеÄÀûÓᣲ½Ö裺ÏÈÀûÓÃÆ¤·ô±í¿Æ¼¼Êõ¶Ï¸ù´´Ã滵ËÀ×éÖ¯ºó£¬ÀûÓÃʪÈóÉÕÉ˸àÔì¾ÍÈâÑ¿£¬¶øºó°´À£Ññ´´Ãæ£ºÈ¡Æ¤Ãæ»ý=20¡«30¡Ã1µÄ±ÈÀýÈ¡ÈͺñƤ¼ô³É΢Á£Æ¤Á£ºóÖÖÖ²ÓÚÈâÑ¿ÖУ¬ÔÙÓÃʪÈóÉÕÉ˸àÅàֲ΢Á£Æ¤Ö±ÖÁ±íƤ»¯½¨¸´´´Ãæ¡£Á˾֣º2005Äê9ÔÂ~2007Äê9ÔÂÎÒÃÇÓÃ΢Á£Æ¤ÖÖÖ²ÊõÒ½ÖÎ31ÀýƤ·ôÂýÐÔÀ£Ññ»¼Õß»ñµÃÖÐÒâ³ÉЧ¡£½áÂÛ£ºÎ¢Á£Æ¤ÖÖÖ²Êõ½áºÏʪÈóÉÕÉ˸àÒ½ÖÎÆ¤·ôÂýÐÔÀ£Ññ£¬ ÊÖÊõ²Ù×÷µ¥Ò»£¬Êõºó¹©Æ¤ÇøÓúºÏºÃ£¬À£ÑñÇø½¨¸´ºóƤ·ôÈáÈí¡¢ñ£ºÛÉÙ¡¢Ö°ÄÜÓ°ÏìС £»ÓÉÓÚÊÖÊõÈ¡Æ¤Ãæ»ýÔ¶Ô¶Ó×ÓÚ´´Ã棬΢Á£Æ¤Ö±½ÓÖÖÖ²ÓÚ´´ÃæÈâÑ¿ÄÚ£¬Êõºó¶Ô´´Ãæ¹Ø½Ú»î¶¯ÒªÇóÏà¶ÔµÍ£¬ËùÒÔ»¼Õß˳´ÓÐԺᣱ¾·¨±×¶ËÊDz¿ÃŲ¡ÀýÖÖÖ²µÄ΢Á£Æ¤³É»îÂʽϵÍ£¬ÐëÂÅ´ÎÖÖÖ²£¬½¨¸´¹¦·ò¿ÉÄܽϳ¤¡£
¡¾¹Ø¼ü´Ê¡¿¡¡ÔÙÉúÒ½ÁƼ¼Êõ;Ƥ·ôÂýÐÔÀ£Ññ £»×ÔÌå΢Á£±íÆ¤ÒÆÖ²

Clinical Report of Repair of Chronic Skin Ulcers with Autografting Microparticle Skin£®HE Ren-liang1, YU Zhi-he2, LIU Ying-xiang2, et al£®1£®School of Traditional Medicine, Southern Medical University, Guangzhou City, Guangdong Province, 516000, China; 2£®Dept£®of Dermatology, the People's Hospital, Huangpu District, Zhongshan City, Guangdong Province, 528429, China£®
¡¾Abstract¡¿¡¡Objective: To explore the epidemic repair of chronic skin ulcers treating with autografting microparticle skin£®Method: After necrotic tissue removed at the wound with surgery method and granulation tissue cultured with MEBO, microparticle skin tablet prapared with split-thickness skin according to the proportion of 20~30:1 (Ulcer area : skin area) and then the skin tablets were cultivated at granulation with MEBO till epidemic repair completed£®Result: All 31 cases of chronic ulcer patients collected from Sep£® 2005 to Sep£®2007 were treated with microparticle skin tablets culture and  satisfactory effect was obtained£®Conclusion: Treating chronic ulcers with microparticle skin tablets autografting cultured by MEBO has advantages£¬such as simple operation, good repair effect for donate site wound; and soft skin, less scar formation and better joint function obtained at healed ulcer wound site£®Because the area of donor site was far less than that of ulcer wound and microparticle skin tablets were planted into granulation directly, little requirement for the joint function was required after surgery, so it is more acceptable by the patient£®But, there are some disadvantages including lower survival rate of microparticle skingrafting£®For some patients, multiple grafting and longer repair time are required sometime£®
¡¾Key words¡¿¡¡Chronic skin  ulcer; Auto-microparticle skingrafting; Plantation
ÓÉÓÚ²»×ãÓÕµ¼±íƤ³É³¤·¢ÓýµÄ΢»·¾³£¬Ìå±íÁ¢ÌåÔì¾ÍµÄ±íƤϸ°ûûÓеäÐÍµÄ±íÆ¤½á¹¹[1]£¬Òò¶ø²»ÄÜÓÐЧµØ½¨¸´Æ¤·ô´´Ã档ʪÈóÉÕÉ˸ࣨ¼ò³ÆMEBO£©×÷Ϊ´´Ã潨¸´µÄÒ»ÖÖÓµÓÐ×ÔÖ÷֪ʶ²úȨµÄÖÐÒ©Ôì¼Á£¬²»½öÔÚԭλӵÓиÉϸ°ûÅàÖ²×÷Óã¬ÔÚÌå±íÒ²ÓµÓиÉϸ°ûÅàÖ²×÷ÓÃ[2]¡£ÎªÁ˹۲ì×ÔÌå΢Á£Æ¤ÖÖÖ²Êõ½áºÏMEBOÒ½ÖÎÆ¤·ôÂýÐÔÀ£ÑñµÄÁÆÐ§£¬ÎÒÃÇÀûÓÃ×ÔÌå΢Á£Æ¤ÖÖÖ²Êõ½áºÏMEBO¶Ô31ÀýȱËðÔÚ5cm2ÒÔÉÏµÄÆ¤·ô´´Ãæ½øÐн¨¸´£¬²¢½øÐÐÈ«³ÌµÄÁÙ´²¹Û²ì¡£Ïֻ㱨ÈçÏ£º
1£®ÁÙ´²×ÊÁÏ
1£®1£®Í¨³£×ÊÁÏ£ºÈ«Êý²¡Àý¾ùΪÎÒ¿Æ×¡Ôº²¡Àý£¬ÆäÖÐÄÐ18Àý£¬Å®13Àý £»×î´ó´ºÇï78Ë꣬×îÓ×´ºÇï19Ë꣬¾ùÔÈ´ºÇï52.7Ëê £»²¡³Ì×5Ä꣬×î¶Ì4¸öÔ£¬¾ùÔȲ¡³Ì9.6¸öÔ £»ÌÇÄò²¡ÐÔÆ¤·ôÀ£Ññ7Àý£¬´´ÉËÐÔÀ£Ññ5Àý£¬Ñ¹Á¦ÐÔÀ£Ññ6Àý£¬ °©ÐÔÀ£Ññ3Àý£¬ÉÕÉË²Ð´æ´´ÃæÀ£Ññ5Àý£¬·ÅÉäÐÔÀ£Ññ2Àý£¬ÊÖÊõÒþÓïÓúºÏ²»Á¼ÐÔÀ£Ññ3Àý £»À£ÑñÃæ»ý×îÓ×2.3cm×2.8cm£¬×î´ó15cm×12cm£¬¾ùÔÈ4cm×2.3cm¡£
1£®2£®Õï¶Ï³ß¶È£º²ÎÕÕÈì´¯ Wagner·Ö¼¶1~2¼¶½øÐÐÀ£Ññ·Ö¼¶¡£
1£®3£®ÈëÑ¡²¡Àý£ºÐķθÎÉöÖ°ÄÜÓÅÁ¼£¬Æ¤·ôÀ£Ññ²¡³Ì1¸öÔÂÒÔÉÏ¡¢Ãæ»ý´óÓÚ5cm2Õß¡£
1£®4£®Åųý²¡Àý£º£¨1£©ÔÚ½ÓÊÜÌÇÆ¤Öʼ¤ËØ¡¢ÃâÒßÒÖÔì¼Á¼°Ö×Áö»¯ÁÆÕß¡££¨2£©ÔÚ½ÓÊÜ»ò´Óǰ1 ¸öÔÂÄÚ½ÓÊܹý³É³¤Òò×ÓÒ½ÖÎÕß¡££¨3£©²»Ô޳ɽÓÊÜ×ÔÌå΢Á£Æ¤ÖÖÖ²ÊÖÊõÕß¡££¨4£©À£Ññ´´ÃæÃæ»ý<5cm2Õß¡£
1£®5£®ÌÞ³ý²¡Àý£ºÒò¸÷ÀàÔ­ÒòÖÐ;Í˳ö»òδʵÏÖÒ½ÖεϼÕß¡£
1£®6£®´´ÃæÆÀ¹À³ß¶È£º
1£®6£®1£®´´Ãæ·Ö¼¶¼°¼Ç·Ö£º1¼¶£ºÕæÆ¤È«²ãÊÜË𣬴©ÈëÆ¤ÏÂ×éÖ¯£¬µ«ÉÐδ´©Í¸½îĤ¼°¼¡Èâ²ã £»2¼¶£ºÈ«Æ¤²ãÇÖº¦£¬´©Í¸½îĤ£¬Éî´ï¼¡Èâ²ã £» 3¼¶£ºÈ«Æ¤²ãÇÖº¦£¬´©Í¸½îĤ¼°¼¡Èâ²ã£¬Éî´ï¹Ç÷À£¬Ö¹Ç÷À±©Â¶¡£
1£®6£®2£®ÉË¿ÚÆÀ¹À£º²ÎÕÕ¡¶ÊµÓÃÉ˿ڻ¤Àíѧ¡·ÉË¿ÚÆÀ¹À±íÔì¶©ÈçÏ£º
£¨1£©À£Ññ±í±íÉ«Ôó£º
4·Ö£ººìÈó £»
3·Ö£ºµ­ºìÉ« £»
2·Ö£º°µºìÉ« £»
1·Ö£º×ϰµ»ò²Ò°×É«¡£
£¨2£©ÉË¿ÚÉøÒºÁ¿£º
4·Ö£ººÜÉÙÁ¿£ºÉ˿ڱí±íʪÈ󣬵«ÎÞ·¨ÕÉÁ¿³öÉøÒºÁ¿£¬»òûÓÐÉøÒº £»
3·Ö£ºÉÙÁ¿£ºÉË¿ÚÉø³öÒºÉÙ£¬Õ´ÊªÄÚ²ã·óÁÏ≤25£¥ £»
2·Ö£ºÖÐÁ¿£ºÉø³öҺմʪÄÚ²ã·óÁÏ26%¡«75£¥ £»
1·Ö£º´óÁ¿£ºÉø³öҺմʪÄÚ²ã·óÁÏ76%¡«100£¥¡£
£¨3£©ÐÂÉúÈâÑ¿×éÖ¯
    4·Ö£ºÐÂÏÊÈâÑ¿×éÖ¯ÔÚ´´ÃæÉ¢²¼≥76% £»
    3·Ö£ºÐÂÏÊÈâÑ¿×éÖ¯ÔÚ´´ÃæÉ¢²¼51%¡«75% £»
    2·Ö£ºÐÂÏÊÈâÑ¿×éÖ¯ÔÚ´´ÃæÉ¢²¼26%¡«50% £»
¡¡¡¡1·Ö£ºÐÂÏÊÈâÑ¿×éÖ¯ÔÚ´´ÃæÉ¢²¼≤25%¡£
£¨4£©ÐÂÉúÉÏÆ¤×éÖ¯
4·Ö£ºÐÂÉúÉÏÆ¤×éÖ¯Ëù¸²¸Ç´´ÃæÃæ»ý≥76% £»
3·Ö£ºÐÂÉúÉÏÆ¤×éÖ¯Ëù¸²¸Ç´´ÃæÃæ»ý51%¡«75% £»
2·Ö£ºÐÂÉúÉÏÆ¤×éÖ¯Ëù¸²¸Ç´´ÃæÃæ»ý26%¡«50% £»
1·Ö£ºÐÂÉúÉÏÆ¤×éÖ¯Ëù¸²¸Ç´´ÃæÃæ»ý≤25%¡£
1£®7£®Ò½Öβ½Ö裺ËùÓÐÄÉÈëÕß½øÈë×êÑÐʱ¾ùÓèÒÔ·î¸æ²¢Ç©ÊðÖªÇéÔÞ³ÉÊé¡£
1£®7£®1£®È«ÉíÒ½ÖΣºÁ½×鲡È˾ùʹÓ㺣¨1£©Õë¶ÔÔ­·¢²¡µÄÒ½ÖÎÔ̺¬½µµÍѪÌÇ¡¢¼ÓÇ¿ÓªÑøÖ§³Ö¡¢¸ÄÉÆÎ¢Ñ­»·µÈ £»£¨2£©Æ¾¾Ý´´ÃæÏ¸¾ú¼°Õæ¾úÔì¾Í¼°Ò©ÃôÁ˾ÖÑ¡ÔñÏàÓ¦µÄ¿¹¾úÒ½ÖΡ£
1£®7£®2£®Î¢Á£Æ¤ÖÖÖ²Êõ£º£¨1£©´´ÃæÔڶϸù½¹ð衢ŧðèÒÔ¼°»µËÀ×éÖ¯ºó£¬ÓÃMEBOÒ©É´¸²¸Ç´´Ã棬¼õѹ°üÔú£¬ÖðÈÕ1´Î£¬Ôì¾ÍÐÂÏʵÄÈâÑ¿£¬»»Ò©Ê±¼ÈÒª×öµ½Î¢´´ËãÕÊ»µËÀ×éÖ¯£¬ÓÖҪʹ´´ÃæÉÙÊܴ̼¤£¬ÉÙ³öѪ¡££¨2£©Î¢Á£Æ¤ÖÔ줻úÓö£ºÉË¿ÚÉø³öÒºÉÙ£¬Õ´ÊªÄÚ²ã·óÁÏ≤25£¥£¬ÐÂÏÊÈâÑ¿×éÖ¯ÔÚ´´ÃæÉ¢²¼51%¡«75%ÒÔÉÏ£¬´´ÃæÆÀ·Ö8·ÖÒÔÉÏ¡££¨3£©Î¢Á£Æ¤Ôì×÷£ºÍ¨Àý°ÎÈ¡¹©Æ¤Çø£¬Ïû¶¾Âé×íºó£¬°´È¡Æ¤Ãæ»ý£º´´ÃæÃæ»ý=1£º20¡«30µÄ±ÈÀýÈ¡ÈͺñƤƬ£¬ÔÚÎÞ¾úÉúÀíÑÎË®Öмô³É0.1cm~0.2cm´óÓ×µÄ΢Á£Æ¤¡££¨4£©Î¢Á£Æ¤ÖÖÖ²£ºÏÈͨÀýÏû¶¾´´Ã棬ÓÃÑÛ¿ÆÎÞ³ÝÄ÷½«Î¢Á£Æ¤ÖÖÖ²ÓÚ´´ÃæÈâÑ¿ÖУ¬¾àÀëÔ¼0.3cm~0.5cm£¬Éî¶ÈÔ¼0.2cm~0.3cm£¬ÎÞ¾úÉ´²¼Ñ¹ÆÈֹѪ£¬¶øºó¸²¸ÇÒ»²ãMEBOÒ©É´£¬ÎÞ¾úÉ´²¼°üÔú£¬Ã¿Ìì»»Ò©1´Î¡£´ýƤµºÀ©´óÏ໥ÈںϺóÔÙ²¿ÃÅ·À°Ì´¦Öá£
1£®7£®3£®¹Û²ì¹¦·ò£ºÊõºó28Ìì¡£
1£®8£®¹Û²ìÖ¸±ê£º
1£®8£®1£®´´ÃæÃæ»ý£ºÓÃͨÃ÷·½¸ñÖ½£¬ÔÚ»¼ÕßÈëԺʱÕÉÁ¿´´ÃæµÄÃæ»ýΪ³õÊ¼Ãæ»ý£¬ÁƳÌʵÏÖʱÕÉÁ¿¸÷ʱÏàµãµÄ½¨¸´Ãæ»ý¡£ÍÆË㹫ʽ£º´´ÃæÓúºÏÃæ»ý°Ù·Ö±È£½£¨ÓúºÏÃæ»ý£¯³õÊ¼Ãæ»ý£©×100£¥¡£Ñ¡È¡Adobe ImageReady 7.0ºÍOsirisÈí¼þÍÆËã´´ÃæÃæ»ý¡£

 

¶íÂÞ˹¹ó±ö»á¡¤(Öйú)¼¯ÍÅ

1£®8£®2£®´´ÃæÇé¿ö£ºÔÚÒ½ÖÎǰºóÒÀÕÕ´´ÃæÆÀ¼Û³ß¶È¼Æ·Ö£¬ ²¢ÉãÓ°Áô´æÕÕÆ¬½øÐÐǰºó¶Ô±È¡£
1£®9£®Ò½ÖÎÁ˾֣º
1£®9£®1£®ÆÀ¼Û³ß¶È£º°´´´ÃæÆÀ¹À³ß¶È¼Æ·Ö×ܵ÷ֽøÐÐÆÀ¼Û£¬ÖÎÓú£º16·Ö £»ÓÐЧ12·Ö¡«15·Ö £»ÎÞЧ<12·Ö¡£
1£®9£®2£®ÁÙ´²¹Û²ìÁ˾֣ºÒ½ÖÎ4Öܺó×ÛºÏÆÀ·Ö16·ÖµÄ25Àý£¬15·ÖµÄ2Àý£¬12·Ö4Àý¡£Ò½ÖÎ8ÖܺóÖ»ÓÐ2Àý×Ü»ý·ÖΪ12·Ö £»Ò½ÖÎ12ÖܺóÈ«Êý²¡Àý»ý·Ö¾ù´ï15·ÖÒÔÉÏ¡£
2£®½áÂÛ
4Öܹ۲ìÆÚÖÎÓú25Àý£¬ÁÆÐ§ÓÅÁ¼6Àý¡£Î¢Á£Æ¤ÖÖÖ²Êõ½áºÏƤ·ôԭλÔÙÉú¼¼ÊõÒ½ÖÎÆ¤·ôÂýÐÔÀ£Ññ£¬ ÊÖÊõ²Ù×÷µ¥Ò»£¬Êõºó¹©Æ¤ÇøÓúºÏºÃ£¬À£ÑñÇø½¨¸´ºóñ£ºÛÉÙÇÒÈáÈí£¬Ö°ÄÜÓ°ÏìС £»ÓÉÓÚÊÖÊõÈ¡Æ¤Ãæ»ýÔ¶Ô¶Ó×ÓÚ´´Ã棬΢Á£Æ¤Ö±½ÓÖÖÖ²ÓÚ´´ÃæÈâÑ¿ÄÚ£¬Êõºó¶ÔÏ޶ȹؽڻҪÇóÏà¶ÔµÍ£¬ËùÒÔ»¼Õß˳´ÓÐԺᣵ«²¿ÃŲ¡ÀýÖÖÖ²µÄ΢Á£Æ¤³É»îÂʽϵÍ£¬ÐèÂÅ´ÎÖÖÖ²£¬½¨¸´¹¦·ò½Ï³¤¡£
3£®»áÉÌ
Ƥ·ô´´Ã潨¸´Ò»ÏòÊÇҽѧ½ç³Ö¾Ã¹Ø×¢µÄ¿ÎÌâ[3~5]¡£Ä¿Ç°¹úÄÚ±íѧÕß¶ÔÆ¤·ôÂýÐÔÀ£ÑñµÄÒ½ÖνøÐÐÁË¿í·º×êÑУ¬ÎÞÊýÒÔΪÊÖÊõÊǽÚÔìºÍ¾ÀÕý²¡Òò»ù´¡ÉϵÄÒ»ÖÖ׿ÓгÉЧµÄÒ½Öμ¿Á©£¬µ«ÓÉÓÚÂýÐÔÀ£Ññ»¼Õß´ó¶àͬʱ¹é²¢È«ÉíÐÔ¼²²¡£¬ÈçÌÇÄò²¡£¬ÖзçºóµÄÖ«Ìå̱»¾£¬¼¹×µ´´ÉËËùÖµĽØÌ±£¬ÑϳÁÈ«ÉíÓªÑø²»Á¼µÈ£¬Ê¹´óÃæ»ýƤ·ôÒÆÖ²»òƤ°ê×ªÒÆµÈÊÖÊõ·½Ê½Êܵ½ºÜ´óÏÞ¶È¡£·ÇÊÖÊõÒ½Öβ½ÖèÔ̺¬£ºÖÐÒ½ÖÎÁÆ¡¢ÎïÀíÒ½ÖΡ¢Ï¸°ûÒò×ÓÒ½ÖΡ¢Æ¤·ô×éÖ¯¹¤³ÌʹÓᢹÇËè¼ä³äÖʸÉϸ°ûÒ½ÖεÈ£¬µ«¸÷×÷Õß±¨Â·µÄÁÆÐ§²»Ò»¡£ÊªÈóÉÕÉ˸àÓµÓÐìÉú¼¡¡¢»îѪ»¯ðöµÄ¹¦Ð§£¬ÔÚΪ´´ÃæÌṩÉúÀíʪÈó»·¾³µÄͬʱ£¬ÄÜʹ»µËÀ×éÖ¯ºÍ´úл²úÆ·ÎÞΣÏÕµÄÓɱíÈëÀïµØÒº»¯¡¢Åųö£¬²Ð´æÆ¤·ô×éÖ¯Ïò¸Éϸ°û·½Ïòת»¯£¬×îÖÕʵÏÔ줷ôԭλÔÙÉúÓúºÏ[6]¡£¹ú±íѧÕßҲ֤ʵMEBO¶ÔƤ·ôÀ£ÑñÓÐÓÅÁ¼µÄÁÆÐ§[7]¡£ÂýÐÔÌå±íÀ£ÑñµÄÌØµãÊÇ´´ÔµÏËά×éÖ¯»·±§¡¢´´ÖÜÉÏÆ¤Ï¥ÐÐÊÜÏÞ £»´´ÃæÈâÑ¿×éÖ¯Óë´´ÖÜÉÏÆ¤×éÖ¯¸ôÀë £»´´ÃæÈâÑ¿×éÖ¯ÀÏ»¯¡¢²Ò°×£¬ÎÞÆ¤·ô×éÖ¯²Ð´æ¡£Òò¶øÑî¹úÃ÷[2]¡¢Íõ¼Ì»¸[8]¡¢ºÎÈÊÁÁ£Û9£ÝµÈ²ÉÈ¡MEBOÔì¾ÍÐÂÏÊÈâÑ¿ÔÙ×÷΢Á£Æ¤ÖÖÖ²Ò½Ö΢ó¶ÈÉîÐÍÉÕÉË´´Ãæ»ñµÃÁËÓÅÁ¼³ÉЧ£¬ÎÒÃÇÀûÓÃMEBOÒ©¸à½áºÏ×ÔÌå΢Á£Æ¤ÖÖÖ²Ò½ÖÎÂýÐÔÆ¤·ôÀ£ÑñÅú×¢£¬¸Ã¼¼Êõ²Ù×÷µ¥Ò»£¬ÎÞÐèÌØÊâÊÖÊõÉ豸ºÍÕòÍ´ÒªÇó £»¾­ÅàÖ²µÄÐÂÉúƤÈáÈí£¬¹Ø½ÚÖ°Äܸ´Ô­ºÃ£¬»¼ÕßÄÍÊÜÐԺã¬Ò½ÖγÉЧÏÔÖø£¬ÓÈÆäºÏÓÃÓÚ²»ÄܽÓÊÜ´óƬֲƤµÄ»¼Õß¡£
²Î ¿¼ ÎÄ Ï×
[1]Lamme EN£¬Van Leeuwen RT£¬Brandsma K£¬et al£®Higher numbers of autologous fibroblasts in an artificial substitute improve tissue regeneration and modulate scar tissue formation[J] £®J Pathol£¬2000£¬190£º595~603£®
[2] Ñî¹úÃ÷£¬ÕÔ¿¡Ï飬ӺÕþ£®MEBT¹²Í¬ÈâÑ¿´´ÃæÎ¢Á£Æ¤ÖÖÖ²Ò½ÖÎÉî¢ó¶ÈÉÕÉË[J] £®ÖйúÉÕÉË´´ÑñÔÓÖ¾£¬1998£¬34£¨1£©£º28~29£®
[3] Scott PG£¬Ghahary A£¬Tredget EE£®Molecular and cellular aspects of fibrosis following thermal injury[J] £®Hand Clin£®2000£¬16£º271~287£®
[4] ¸¶Ó×±ø£¬ËïͬÖù£¬ÑîÒø»Ô£¬µÈ£®¼îÐÔ³ÉÏËάϸ°û³É³¤Òò×ÓºÍת»¯³É³¤Òò×Ó-βÔÚÀ£ÑñÓëÔöÉúÐ԰̺Û×éÖ¯Öеıí°×¼°Æä¶Ô´´É˽¨¸´µÄÓ°Ïì[J] £®Öйú½¨¸´³Á½¨±í¿ÆÔÓÖ¾£¬2000£¬14£º271~274£®
[5] Ñî´ºÃ÷£®¼±Ö¢±í¿ÆÑ§[M] £®³õ°æ£¬±±¾©£ºÈËÃñ¾üÒ½³ö°æÉ磬2001£º162~164£®
[6] ÐìÈÙÏ飬ÐíÔö»£®ÉÕÉËʪÐÔÒ½ÁƼ¼Êõ¶Ô±íƤÔÙÉú¸Éϸ°û×÷ÓõÄ×êÑÐ[J] £®ÖйúÉÕÉË´´ÑñÔÓÖ¾£¬2000£¬3£º41~42£®
[7] Atiyeh BS£¬ Ioannovich J£¬ Magliacani G£¬ Masellis M£¬ Costagliola M£¬ Dham R£®The efficacy of MEBO £¨moist exposed burn ointment£© in the management of cutaneous wounds and ulcers£º a pilot study[J] £®Letter-to-the-editor£¬ Ann Plast Surg 2002£¬48£º 226~227£®
[8] Íõ¼Ì»¸£¬ÕŲÊϼ£®MEBOÒ½ÖιÌÖ´ÐÔÂýÐÔÀ£Ññ168Àý[J] £®ÖйúÉÕÉË´´ÑñÔÓÖ¾£¬1998£¬34£¨4£©£º36~37£®
[9] ºÎÈÊÁÁ£¬ÁõÓ¢Ï飬³ÂÓÀÁˆ£¬µÈ£®×ÔÌå΢Á£Æ¤ÖÖÖ²ÉÏÆ¤»¯ÔÙÉú½¨¸´´óÃæ»ýÉî¶ÈÉÕÉË´´Ãæ×é֯ѧ¹Û²ì[J] £®ÖйúÉÕÉË´´ÑñÔÓÖ¾£¬2007£¬19£¨1£©£º7~10£®
¡¾×÷Õß¼ò½é¡¿
ºÎÈÊÁÁ£¨1968~£©£¬ÄУ¨ºº×壩£¬ºþÄϰ²ÈÊÈË£¬ÄÏ·½Ò½¿Æ´óѧÔÚ¶Áҽѧ˶ʿ£¬ÖØÒª´ÓÊÂÆ¤·ô¿Æ¡¢Æ¤·ô´´Ã潨¸´¡¢Æ¤·ô±í¿ÆÁÙ´²ºÍ¿ÆÑУ¬¿ÆÖ÷ÈΣ¬¸±Ö÷ÈÎҽʦ£®
ÓàÖ¾ºÍ£¨1971~£©£¬ÄУ¨ºº×壩£¬¹ã¶«ÓÜÁÖÈË£¬±ÏÒµÓÚÓÜÁÖ´óѧ£¬ÖØÒª´ÓÊÂ±í¿ÆÁÙ´²ºÍ¿ÆÑÐÒÔ¼°Ò½ÔºÖÎÀí£¬¸±Ôº³¤£¬¸±Ö÷ÈÎҽʦ£®
ÁõÓ¢Ï飨1953~£©£¬ÄУ¨ºº×壩£¬¹ã¶«ÓÜÁÖÈË£¬±ÏÒµÓÚÓÜÁÖҽѧԺ£¬ÖØÒª´ÓÊÂ±í¿ÆÁÙ´²ºÍ¿ÆÑм°Ò½ÔºÖÎÀí£¬Ôº³¤£¬¸±Ö÷ÈÎҽʦ£®

¡¾ÍøÕ¾µØÍ¼¡¿